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The recent explosion in large-scale genetic association study data
and genotyped biobanks offers an unprecedented opportunity to
leverage natural genetic variation for inferring causal effects using
the Mendelian randomization paradigm [1, 2]. In this approach,
genetic variants are used to proxy modification of an exposure and
study its effect on an outcome [1]. The random allocation of genetic
variants means that such associations are relatively devoid of the
confounding and reverse causation bias that can hinder causal infer-
ence in observational research [1]. The application of this approach to
a range of clinical outcomes across the phenome allows for efficient
investigation of the broad health implications of a genetically proxied
exposure [3, 4].
In the paper by King and colleagues, the authors perform Mende-
lian randomization across the phenome (i.e. phenome-wide Mende-
lian randomization analysis) to investigate the broad clinical
implications of smoking [5]. They find the expected associations of
genetically predicted smoking intensity with respiratory, cardiovas-
cular and cancer outcomes, and also identify more novel associations
including links with acute renal failure and septicaemia [5]. In total,
the authors generate genetic evidence for detrimental effects of
smoking on 28 disease outcomes. The findings provide important
insight, both adding to existing work, and also offering useful advan-
ces. By considering smoking intensity as the exposure, the findings
support the notion that efforts to reduce the number of cigarettes
smoked per day will likely still be of benefit where complete smoking
cessation is not achievable. The association of higher geneticallyDOI of original article: http://dx.doi.org/10.1016/j.eclinm.2020.100488.
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adverse clinical outcomes but no evidence of any beneficial effects
adds unwavering supports to the detrimental effects of smoking on
health.
The innovative methodology employed by King and colleagues
builds on previous work using genetic variants related to smoking
heaviness in smokers as genetic proxies for studying the effect of
smoking intensity [6]. This further allows for a negative control
sample in those that have never smoked. Through hypothesis-free
untargeted analysis, the phenome-wide association study
approach additionally allows for wider investigation than in previ-
ous studies, such as those considering cardiovascular outcomes
specifically [7].
In their findings, King and colleagues make useful insight
towards prioritising further research efforts [5]. Of note however,
the Mendelian randomization approach has limitations and should
not be used to infer the effect of a clinical or public health interven-
tion that reduces smoking intensity. Importantly, the Mendelian
randomization estimates may be biased by pleiotropic effects of the
variants on the considered outcome through pathways unrelated to
smoking intensity. Despite the best efforts of the authors [5], it is
never possible to completely exclude the possibility of bias related
to such pleiotropic effects [8]. For example, the genetic determi-
nants of smoking are closely related to those of alcohol consump-
tion, and as such it is unclear whether the identified Mendelian
randomization association of smoking intensity with alcoholism
represents evidence supporting causal effect or simply shared
genetic aetiology. Other considerations are that Mendelian random-
ization estimates typically relate to the cumulative lifetime effect of
varying an exposure (such as smoking intensity), while in practice
an individual might differentially vary their smoking intensity
throughout the life course. While such analyses may therefore be
better served towards identifying causal relationships rather than
estimating causal effects, there are two further caveats. Firstly, the
consideration of a large number of outcomes forces a correction for
multiple testing, which may in turn increase risk of false negative
findings. Secondly, while such analyses may provide evidence to
support a causal effect of smoking intensity on particular outcomes,
they cannot in isolation offer mechanistic insight.er the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
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genetic data and individual-level genetic data linked with electronic
health care records [9], there is increasing opportunity to efficiently
study the broad health implications of different exposures using the
Mendelian randomization paradigm within a phenome-wide associa-
tion study context [2]. Smoking is a leading cause of morbidity and
mortality worldwide, and the current effort by King and colleagues
represents an innovative approach for exploring the breadth of this
[5]. Further work is now required to triangulate findings with other
sources of evidence [10], provide mechanistic insight, and explore
the effects of clinical and public health interventions that aim to
reduce smoking.
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